Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierFortrea Holdings Inc. is a leading global contract research organization (“CRO”), providing biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology and medical device customers. We provide phase I through IV clinical trial management, clinical pharmacology, and consulting services for our customers. For more than 30 years, we have supported our global pharmaceutical, biotechnology, and medical device customers across more than 20 therapeutic areas, providing agile delivery models that include Full Service, Functional Service Provider (“FSP”), and Hybrid structures.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Q1 2026 · $636.5MThe company’s own SEC segment disclosure.
- North America$296.8M47%
- Europe$213.9M34%
- Other Geographical Areas$125.8M20%
Fortrea Holdings Inc. (FTRE) reported revenue of $637M in Q1 2026 (quarter ended March 31, 2026), down 2.3% from the same quarter a year earlier. That came with a gross margin of 19% and net loss of $24M. For the full year FY2025, revenue was $2.72B (+1.0% year on year) and net income −$986M. Its largest region in 2026-Q1 was North America at $297M, 47% of the disclosed total, just ahead of Europe at 34%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.